Candel Therapeutics, Inc. logo

Candel Therapeutics, Inc. (CADL) Q3 2024 Earnings

CADL·Reported November 14, 2024·Before market open

Diluted EPS came in at $-0.33.

Diluted EPS
$-0.33
SEC

SEC Filings

Earnings release8-K not filed yet
Quarterly report10-Q · 0000950170-24-126767

Financial Snapshot

Trailing eight quarters through Q3 2024

View all metrics

Revenue

View metric

Net Income

View metric

Operating Cash Flow

View metric

EPS (Diluted)

View metric

Q3 2024 Earnings FAQ

Common questions about Candel Therapeutics, Inc.'s Q3 2024 earnings report.

Candel Therapeutics, Inc. (CADL) reported Q3 2024 earnings on November 14, 2024 before market open.

Candel Therapeutics, Inc. reported diluted EPS of $-0.33 for Q3 2024.

You can read the 10-Q periodic report (0000950170-24-126767) directly on SEC EDGAR. The filing index links above go to sec.gov.